JPWO2011052436A1 - 架橋型人工ヌクレオシドおよびヌクレオチド - Google Patents

架橋型人工ヌクレオシドおよびヌクレオチド Download PDF

Info

Publication number
JPWO2011052436A1
JPWO2011052436A1 JP2011538366A JP2011538366A JPWO2011052436A1 JP WO2011052436 A1 JPWO2011052436 A1 JP WO2011052436A1 JP 2011538366 A JP2011538366 A JP 2011538366A JP 2011538366 A JP2011538366 A JP 2011538366A JP WO2011052436 A1 JPWO2011052436 A1 JP WO2011052436A1
Authority
JP
Japan
Prior art keywords
group
carbon atoms
compound
amino
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2011538366A
Other languages
English (en)
Japanese (ja)
Inventor
聡 小比賀
聡 小比賀
功幸 張
功幸 張
哲也 兒玉
哲也 兒玉
愛子 矢原
愛子 矢原
西田　勝
勝 西田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Osaka NUC
Original Assignee
Osaka University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC filed Critical Osaka University NUC
Publication of JPWO2011052436A1 publication Critical patent/JPWO2011052436A1/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011538366A 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド Ceased JPWO2011052436A1 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009248979 2009-10-29
JP2009248979 2009-10-29
JP2010023209 2010-02-04
JP2010023209 2010-02-04
PCT/JP2010/068409 WO2011052436A1 (ja) 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013244692A Division JP5669073B2 (ja) 2009-10-29 2013-11-27 架橋型人工ヌクレオシドおよびヌクレオチド

Publications (1)

Publication Number Publication Date
JPWO2011052436A1 true JPWO2011052436A1 (ja) 2013-03-21

Family

ID=43921860

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011538366A Ceased JPWO2011052436A1 (ja) 2009-10-29 2010-10-19 架橋型人工ヌクレオシドおよびヌクレオチド
JP2013244692A Active JP5669073B2 (ja) 2009-10-29 2013-11-27 架橋型人工ヌクレオシドおよびヌクレオチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013244692A Active JP5669073B2 (ja) 2009-10-29 2013-11-27 架橋型人工ヌクレオシドおよびヌクレオチド

Country Status (7)

Country Link
US (1) US8541562B2 (https=)
EP (1) EP2495248B1 (https=)
JP (2) JPWO2011052436A1 (https=)
CN (1) CN102596983B (https=)
AU (1) AU2010312751B2 (https=)
CA (1) CA2778171C (https=)
WO (1) WO2011052436A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127280B2 (en) 2010-08-31 2015-09-08 Osaka University Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
EP2792746A4 (en) 2011-12-12 2015-09-16 Nat Cerebral & Cardiovascular Ct OLIGONUCLEOTIDE AND THERAPEUTIC FOR HYPERLIPIDEMIA WITH THIS AS AN ACTIVE SUBSTANCE
EP2862868B1 (en) * 2012-06-18 2020-04-08 Daiichi Sankyo Company, Limited Intermediate for production of nucleoside analogue, and method for producing same
KR101707437B1 (ko) 2012-09-21 2017-02-16 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드
WO2014109384A1 (ja) * 2013-01-10 2014-07-17 塩野義製薬株式会社 架橋型核酸誘導体の製造方法
US20150337002A1 (en) * 2013-01-15 2015-11-26 Shionogi & Co., Ltd. Nucleoside and nucleotide having sulfonamide structure
WO2014126229A1 (ja) 2013-02-18 2014-08-21 塩野義製薬株式会社 含窒素複素環構造を有するヌクレオシド及びヌクレオチド
WO2015020194A1 (ja) * 2013-08-09 2015-02-12 国立大学法人大阪大学 Ａｃｓｌ１に対するアンチセンスオリゴヌクレオチド
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
JP6722586B2 (ja) * 2014-07-10 2020-07-15 賢二 中野 アンチセンス抗悪性腫瘍剤
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
JP2018140938A (ja) * 2015-07-24 2018-09-13 日産化学株式会社 人工ヌクレオシド及び人工ヌクレオチド並びに人工オリゴヌクレオチド
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
CN108603230A (zh) 2015-10-09 2018-09-28 南安普敦大学 基因表达的调节与蛋白质表达失调的筛选
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017119463A1 (ja) * 2016-01-07 2017-07-13 国立大学法人大阪大学 α－シヌクレイン発現抑制剤
WO2017131124A1 (ja) 2016-01-26 2017-08-03 日産化学工業株式会社 一本鎖オリゴヌクレオチド
EP3418289B1 (en) 2016-02-17 2026-04-08 Institute Of Science Tokyo Artificial nucleoside and artificial nucleotide, and artificial oligonucleotide
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
JP2020055750A (ja) * 2017-01-30 2020-04-09 賢二 中野 癌浸潤または転移阻害核酸薬
AU2018215440B2 (en) 2017-02-06 2024-10-24 Nissan Chemical Corporation Single-stranded oligonucleotide
EP3587576A4 (en) 2017-02-21 2021-01-06 Osaka University ANTISENSE OLIGONUCLEIC ACID
US11286275B2 (en) 2017-02-21 2022-03-29 Osaka University Nucleic acid compound and oligonucleotide
EP3603648B1 (en) 2017-03-29 2025-09-17 Shionogi & Co., Ltd Complex of nucleic acid medicine and multibranched lipid
JP7141621B2 (ja) 2017-03-31 2022-09-26 学校法人 愛知医科大学 コンドロイチン硫酸生合成を阻害するアンチセンス核酸
US11273222B2 (en) 2017-05-26 2022-03-15 National Cerebral And Cardiovascular Center Antisense nucleic acid targeting PCSK9
WO2019009298A1 (ja) * 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制剤
WO2019009299A1 (ja) 2017-07-05 2019-01-10 国立大学法人大阪大学 α－シヌクレイン発現抑制するＥＮＡアンチセンスオリゴヌクレオチド
BR112020001430A2 (pt) 2017-07-26 2020-07-28 Nissan Chemical Corporation oligonucleotídeo de fita simples
KR102318434B1 (ko) 2017-08-25 2021-11-01 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
IL272864B2 (en) 2017-08-31 2024-03-01 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis
BR112020018902A2 (pt) 2018-03-20 2021-01-26 Tokyo Institute Of Technology oligonucleotídeo antissenso com toxicidade reduzida
CA3099280A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
JP7473113B2 (ja) * 2018-07-31 2024-04-23 国立大学法人大阪大学 オリゴヌクレオチドを含有する小細胞肺癌治療薬
AU2020227825B2 (en) 2019-02-27 2026-03-26 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
WO2020203896A1 (ja) 2019-03-29 2020-10-08 シスメックス株式会社 新規人工核酸、その製造方法及び用途
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
US20220282248A1 (en) 2019-08-27 2022-09-08 National University Corporation Tokai National Higher Education And Research System Molecular targeted nucleic acid medicine for gastric cancer
WO2021127406A1 (en) * 2019-12-19 2021-06-24 The Regents Of The University Of California Methods of producing target capture nucleic acids
WO2021132648A1 (ja) * 2019-12-27 2021-07-01 ルクサナバイオテク株式会社 Ｒｅｃｑｌの発現を阻害するアンチセンスオリゴヌクレオチド及びその用途
WO2021177267A1 (ja) 2020-03-02 2021-09-10 田辺三菱製薬株式会社 ｍｉＲ－３３ｂ阻害物質による動脈瘤の予防または治療
US20230113556A1 (en) 2020-03-26 2023-04-13 National Cerebral And Cardiovascular Center Antisense nucleic acid targeting apoc3
CN115916262A (zh) 2020-04-21 2023-04-04 旗舰创业股份有限公司 双官能分子及其使用方法
CN115867657A (zh) 2020-05-11 2023-03-28 斯托克制药公司 用于治疗疾患和疾病的opa1反义寡聚物
CN116322706B (zh) 2020-09-25 2025-12-05 株式会社理真思 新人工核酸、其制造方法和用途
CN116507727A (zh) 2020-11-06 2023-07-28 住友制药株式会社 Rps25基因的表达和/或功能调节剂
US20240148775A1 (en) 2021-02-25 2024-05-09 Osaka University Oligonucleotide for inducing n-exon skipping during rest mrna precursor processing
EP4331606A4 (en) 2021-04-30 2025-05-07 Kyoto University PREVENTION OR TREATMENT OF MYOPATHY USING A MIR-33B INHIBITOR
US20240247263A1 (en) 2021-05-06 2024-07-25 Luxna Biotech Co., Ltd. Method for designing oligonucleotide having reduced central toxicity
TW202313975A (zh) 2021-05-28 2023-04-01 日商住友製藥股份有限公司 反義核酸
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
EP4458836A4 (en) 2021-12-27 2025-05-21 Riken Genesis Co., Ltd. Novel artificial nucleic acid, method for producing same, and use of same
EP4495242A1 (en) 2022-03-17 2025-01-22 Aichi Medical University Antisense nucleic acid capable of inhibiting biosynthesis of chondroitin sulfate
WO2024101446A1 (ja) 2022-11-10 2024-05-16 ルクサナバイオテク株式会社 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法
JPWO2024181416A1 (https=) 2023-02-28 2024-09-06
JPWO2024257847A1 (https=) 2023-06-16 2024-12-19
JPWO2025005265A1 (https=) * 2023-06-30 2025-01-02
US20250368996A1 (en) 2024-05-14 2025-12-04 Aligos Therapeutics, Inc. Modified antisense oligonucleotides for treating hepatitis b virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516256A (ja) * 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
WO2005021570A1 (ja) * 2003-08-28 2005-03-10 Gene Design, Inc. Ｎ−０結合性架橋構造型新規人工核酸

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1481983A4 (en) 2002-02-13 2008-04-02 Takeshi Imanishi NUCLEOSIDE ANALOGUE AND OLIGONUCLEOTIDE DERIVATIVES CONTAINING A NUCLEOTIDE ANALOGON THEREOF
US9127280B2 (en) * 2010-08-31 2015-09-08 Osaka University Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516256A (ja) * 1998-05-26 2002-06-04 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 二環式糖成分を有する新規ヌクレオシド
WO2005021570A1 (ja) * 2003-08-28 2005-03-10 Gene Design, Inc. Ｎ−０結合性架橋構造型新規人工核酸

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013052629; Ｂｉｏｏｒｇａｎｉｃ ＆ Ｍｅｄｉｃｉｎａｌ Ｃｈｅｍｉｓｔｒｙ Ｌｅｔｔｅｒｓ Ｖｏｌ．８, 1998, ｐｐ．２２１９-２２２２ *
JPN6013052631; Ｊｏｕｒｎａｌ ｏｆ Ｏｒｇａｎｉｃ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．６３， Ｎｏ．２６, 1998, ｐｐ．１００３５-１００３９ *
JPN7013003904; Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｓｙｍｐｏｓｉｕｍ Ｓｅｒｉｅｓ Ｖｏｌ．５３， Ｎｏ．１, 200909, ｐｐ．１１-１２ *
JPN7013003905; Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｓｙｍｐｏｓｉｕｍ Ｓｅｒｉｅｓ Ｖｏｌ．５１, 2007, ｐｐ．１５７-１５８ *

Also Published As

Publication number Publication date
CN102596983A (zh) 2012-07-18
CA2778171A1 (en) 2011-05-05
AU2010312751B2 (en) 2014-07-24
AU2010312751A1 (en) 2012-06-14
US8541562B2 (en) 2013-09-24
US20120208991A1 (en) 2012-08-16
EP2495248B1 (en) 2017-01-11
EP2495248A4 (en) 2013-10-16
CN102596983B (zh) 2016-06-15
EP2495248A1 (en) 2012-09-05
CA2778171C (en) 2017-07-25
WO2011052436A1 (ja) 2011-05-05
JP2014043462A (ja) 2014-03-13
JP5669073B2 (ja) 2015-02-12

Similar Documents

Publication Publication Date Title
JP5669073B2 (ja) 架橋型人工ヌクレオシドおよびヌクレオチド
JP6562517B2 (ja) 架橋型ヌクレオシドおよびヌクレオチド
JP6233903B2 (ja) 架橋型ヌクレオシドおよびヌクレオチド
JP6048982B2 (ja) グアニジン架橋を有する人工ヌクレオシドおよびオリゴヌクレオチド
US7427672B2 (en) Artificial nucleic acids of n-o bond crosslinkage type
JP7441523B2 (ja) ５’位修飾ヌクレオシドおよびそれを用いたヌクレオチド
EP3925965A1 (en) 5'-modified nucleoside and nucleotide using same
US12606589B2 (en) Bridged nucleoside and nucleotide using same
JP7650412B2 (ja) ５′位修飾ヌクレオシドおよびそれを用いたヌクレオチド
JP7751302B2 (ja) 架橋型ヌクレオシドおよびヌクレオチド
JP2023110119A (ja) ５’位修飾ヌクレオシドおよびそれを用いたヌクレオチド
JP7709690B2 (ja) 架橋型ヌクレオシドおよびそれを用いたヌクレオチド
CN118946575A (zh) 5'位修饰核苷和使用其的核苷酸
WO2024101446A1 (ja) 架橋部にグアニジノ構造を有する修飾ヌクレオシドおよびそれを用いたオリゴヌクレオチドの製造方法

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131029

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20131213

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20140225